Pyrimidine Compounds Targeting EGFR Mutants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR tyrosine kinase inhibitors face challenges with drug resistance and poor selectivity, leading to side effects in wild-type EGFR cells, necessitating the development of novel compounds with improved specificity and efficacy against EGFR mutant forms.
Innovation Solution
Pyrimidine compounds with specific structures that inhibit EGFR mutant forms, such as L858R and T790M, while minimizing inhibition of wild-type EGFR, are developed, offering a pharmaceutical composition for treating various cancers with reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If second-generation EGFR inhibitors (afatinib, canertinib, dacomitinib) are used to treat EGFR mutant-resistant cancer, then inhibitory activity against EGFR mutants (L858R, T790M) is improved, but inhibition of wild-type EGFR increases causing drug toxicity and side effects
Solution Approach 1:
The patent applies local quality by designing the pyrimidine compound structure to have specific molecular characteristics that enable selective binding to mutant EGFR conformations. The compound features a pyrimidine core with specific substituent patterns (including fluorine atoms at positions 2 and 4, and specific R1-R6 groups) that create localized interaction zones targeting the mutant ATP-binding pocket, thereby achieving high inhibitory activity against L858R and T790M mutants while minimizing interaction with wild-type EGFR, thus reducing drug toxicity and side effects
2Reliability
If first-generation EGFR inhibitors (gefitinib, erlotinib) are used to treat NSCLC, then treatment effect on EGFR-activated mutant patients is improved, but drug resistance develops within 12-14 months due to T790M mutation
Solution Approach 1:
The patent applies preliminary action by designing the pyrimidine compound to proactively target and inhibit the T790M resistant mutant form of EGFR. The molecular structure is specifically configured with enhanced affinity for the T790M mutation conformation, allowing the drug to preemptively overcome resistance mechanisms before they fully develop or recur, thereby extending the duration of effective treatment beyond what first-generation inhibitors can achieve
Solution Approach 2:
The patent applies parameter changes by modifying key molecular parameters of the EGFR inhibitor structure. The pyrimidine-based compound features specific structural parameters including fluorine substitution patterns, heterocyclic ring configurations, and side chain arrangements that fundamentally alter the binding characteristics compared to first-generation quinazoline inhibitors. These parameter changes enable the drug to maintain high inhibitory activity against both sensitizing mutations (L858R, Exon19 deletion) and resistance mutations (T790M), thereby extending treatment duration and overcoming drug resistance
Data Source
AI summary
The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).